Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Gains from Investment Securities (2016 - 2025)

Marimed (MRMD) has disclosed Gains from Investment Securities for 12 consecutive years, with $372000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 85.07% to $372000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 58.63% decrease, with the full-year FY2024 number at $2.9 million, down 10.94% from a year prior.
  • Gains from Investment Securities was $372000.0 for Q3 2025 at Marimed, up from -$200000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $13.6 million in Q4 2022 to a low of -$6.3 million in Q3 2023.
  • A 5-year average of $1.2 million and a median of $201000.0 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: soared 11733.97% in 2021, then crashed 836.15% in 2023.
  • Marimed's Gains from Investment Securities stood at -$419000.0 in 2021, then skyrocketed by 3348.93% to $13.6 million in 2022, then tumbled by 69.58% to $4.1 million in 2023, then tumbled by 51.61% to $2.0 million in 2024, then plummeted by 81.44% to $372000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Gains from Investment Securities are $372000.0 (Q3 2025), -$200000.0 (Q2 2025), and -$100000.0 (Q1 2025).